Casopitant: Difference between revisions
Created page with "{{Drugbox | Watchedfields = changed | verifiedrevid = 447887505 | IUPAC_name = (2''S'',4''S'')-4-(4-Acetyl-1-piperazinyl)-''N''-[(1''R'')-1-[3,5-bis(trifluoromethyl)phenyl]eth..." |
m Protected "Casopitant": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
(One intermediate revision by one other user not shown) | |||
Line 45: | Line 45: | ||
| smiles = CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C | | smiles = CC1=C(C=CC(=C1)F)[C@@H]2C[C@H](CCN2C(=O)N(C)[C@H](C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C(=O)C | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Casopitant''' (trade names '''Rezonic''' ([[United States|US]]), '''Zunrisa''' ([[Europe|EU]])) is an [[neurokinin 1]] (NK<sub>1</sub>) [[receptor antagonist]] undergoing research for the treatment of [[chemotherapy-induced nausea and vomiting]] (CINV).<ref>{{cite journal |author=Lohr L |title=Chemotherapy-induced nausea and vomiting |journal=Cancer J |volume=14 |issue=2 |pages=85–93 |year=2008 |pmid=18391612 |doi=10.1097/PPO.0b013e31816a0f07 |url=}}</ref> It is currently under development by [[GlaxoSmithKline]] (GSK). | '''Casopitant''' (trade names '''Rezonic''' ([[United States|US]]), '''Zunrisa''' ([[Europe|EU]])) is an [[neurokinin 1]] (NK<sub>1</sub>) [[receptor antagonist]] undergoing research for the treatment of [[chemotherapy-induced nausea and vomiting]] (CINV).<ref>{{cite journal |author=Lohr L |title=Chemotherapy-induced nausea and vomiting |journal=Cancer J |volume=14 |issue=2 |pages=85–93 |year=2008 |pmid=18391612 |doi=10.1097/PPO.0b013e31816a0f07 |url=}}</ref> It is currently under development by [[GlaxoSmithKline]] (GSK). | ||
Line 51: | Line 56: | ||
== See also == | == See also == | ||
* [[Aprepitant]] | * [[Aprepitant]] | ||
* [[Fosaprepitant]] | * [[Fosaprepitant]] | ||
* [[Maropitant]] | * [[Maropitant]] | ||
== References == | == References == | ||
Line 65: | Line 67: | ||
{{Antidepressants}} | {{Antidepressants}} | ||
{{Anxiolytics}} | {{Anxiolytics}} | ||
[[Category:Antiemetics]] | [[Category:Antiemetics]] | ||
Line 73: | Line 75: | ||
[[Category:Piperidines]] | [[Category:Piperidines]] | ||
[[Category:Organofluorides]] | [[Category:Organofluorides]] | ||
[[Category:Drug]] | |||
Latest revision as of 18:43, 18 August 2015
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C30H35F7N4O2 |
Molar mass | 616.26 g/mol |
3D model (JSmol) | |
| |
| |
(verify) |
WikiDoc Resources for Casopitant |
Articles |
---|
Most recent articles on Casopitant |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Casopitant at Clinical Trials.gov Clinical Trials on Casopitant at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Casopitant
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Casopitant Discussion groups on Casopitant Patient Handouts on Casopitant Directions to Hospitals Treating Casopitant Risk calculators and risk factors for Casopitant
|
Healthcare Provider Resources |
Causes & Risk Factors for Casopitant |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]
See also
References
- ↑ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
- ↑ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.
Template:Antiemetics and antinauseants Template:Antidepressants Template:Anxiolytics
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to watched fields
- Antiemetics
- NK1 receptor antagonists
- Amides
- Piperazines
- Piperidines
- Organofluorides
- Drug